These structural motifs can be found in the MC4R antagonist PF-07258669 in phase 1 clinical trials from Pifzer and in the development of the FGFR4 selective inhibitor Roblitinib from Novartis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback